vedolizumab,infliximab
takeda,janssen
['vedolizumab', ' vedo', 'vedo', 'crohn', 'infliximab']
#ddw2023 today the reprevio study. vedolizumab efficacy in preventing 6 month postoperative crohn s disease. now two good randomized controlled studies for postop cd: prevent (infliximab) and reprevio (vedolizumab) 
Professor & Chair, Digestive Disease and Surgery Institute @ClevelandClinic Gastroenterologist in IBD patient-centered care